PMID- 29378101
OWN - NLM
STAT- MEDLINE
DCOM- 20180216
LR  - 20180216
IS  - 0042-8833 (Print)
IS  - 0042-8833 (Linking)
VI  - 84
IP  - 6
DP  - 2015
TI  - [Effects of omega-3 polyunsaturated fatty acids on the state of insulin 
      resistance, the content of some pro- and antiinflammatory factors in patients 
      with type 2 diabetes mellitus and cardiovascular autonomic neuropathy].
PG  - 76-82
AB  - We have investigated the influence of the long-chain omega-3 polyunsaturated fatty 
      acids (omega-3 PUFA) administration on the insulin resistance parameters, levels of 
      high sensitivity C-reactive protein (hsCRP), some pro- and anti-inflammatory 
      cytokines in patients with type 2 diabetes mellitus (T2 DM) and cardiovascular 
      autonomic neuropathy (CAN). The study involved 12 patients with T2 DM without 
      verified cardiovascular diseases (CVD), 36 patients with T2 DM and functional 
      stage of CAN, of median age 50-59 years, disease duration 1-6 years and HbA1c 
      levels - 7.1+/-0.6%. 15 healthy subjects were control group. Screening for CAN, 
      that included five standard cardiovascular tests, was performed. The levels of 
      blood glucose, HbA1c, immunoreactive insulin (IRI), hsCRP, tumor necrosis factor 
      alpha (TNFalpha), interleukin (IL)-6, IL-8 and IL-10 were measured. The index of insulin 
      resistance (HOMA-IR) and TNFalpha/IL-10 ratio were calculated. Patients with T2 DM 
      and CAN were divided into 2 groups: patients of the 1st group (group of 
      comparison, n=15) received standard glucose-lowering therapy; patients of the 2nd 
      group (n=21) received one capsule/day of the omega-3 PUFA ( approximately 90% ethyl ester of PUFA 
      (1000 mg), in particular eicosapentaenoic - 460 mg, docosahexaenoic acid - 380 mg 
      and 4 mg alpha-tocopherol acetate) in addition to the standard therapy. The duration 
      of the study was 3 months. Obtained results showed, that development of CAN in 
      patients with T2 DM is accompanied by increase of the IRI (26.6+/-1.73 mcIU/ml, 
      p<0.001 - compared to the control; p1<0.001 - compared to T2 DM patients without 
      CVD); hsCRP (2.77+/-0.24 mg/l, p<0.001, p1<0,001); TNFalpha (5.75+/-0.24 pg/ml, p<0.001, 
      p1<0.001); IL-6 (5.88+/-0.38 pg/ml, p<0.001, p1<0.001); IL-8 (6.65+/-0.3 pg/ml, 
      p<0.001, p1>0.05); IL-10 (15.86+/-1.4 pg/ml, p<0.05, p1>0.05) levels; TNFalpha/IL-10 
      (44.2+/-3.57%, p<0.01, p1<0.05) and HOMA-IR. After 3 months of treatment no 
      statistically significant changes (p>0.05) of investigated parameters, in 
      particular levels of IRI (-6.8+/-2.0%); hsCRP (-7.2+/-1.63%); TNFalpha (-6.1+/-1.0%); IL-6 
      (-5.8+/-1.77%); IL-8 (-3.9+/-1.57%); IL-10 (-3.7+/-2.34%); TNFalpha/IL-10 (-0.5+/-2.3%) in 
      patients from the group of comparison were found. The administration of omega-3 PUFA 
      to patients with T2 DM and CAN promoted to the statistically significant decrease 
      in hsCRP (-14.8+/-2.91%, p<0.05), TNFalpha (-14.1+/-2.15%, p<0.01), IL-6 (-13.5+/-2.7%, 
      p<0.05), IL-8 (-9.8+/-2.13%, p<0.05), TNFalpha/IL-10 ratio (-34.6+/-1.93%, p<0.05); a 
      slighty decrease in the content of the IRI (-10.3+/-1.1%, p>0.05), IL-10 (+7.9 
      +/-6.42%, p>0.05), HOMA-IR was observed. Obtained results could witness, that 
      prescription of omega-3 PUFA leads to decrease of the proinflammatory immune response 
      activity and allows to consider omega-3 PUFA as a promising medicine in treatment 
      and/or prevention of CAN in patients with DM 2.
FAU - Serhiyenko, V A
AU  - Serhiyenko VA
LA  - rus
PT  - Journal Article
PL  - Russia (Federation)
TA  - Vopr Pitan
JT  - Voprosy pitaniia
JID - 2984870R
RN  - 0 (Cytokines)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Inflammation Mediators)
SB  - IM
MH  - *Cardiovascular Diseases/blood/drug therapy
MH  - Cytokines/blood
MH  - *Diabetes Mellitus, Type 2/blood/drug therapy
MH  - *Diabetic Neuropathies/blood/drug therapy
MH  - Fatty Acids, Omega-3/*administration & dosage
MH  - Female
MH  - Humans
MH  - Inflammation/blood/drug therapy
MH  - Inflammation Mediators/blood
MH  - *Insulin Resistance
MH  - Male
MH  - Middle Aged
EDAT- 2015/01/01 00:00
MHDA- 2018/02/17 06:00
CRDT- 2018/01/30 06:00
PHST- 2015/01/01 00:00 [pubmed]
PHST- 2018/02/17 06:00 [medline]
PHST- 2018/01/30 06:00 [entrez]
PST - ppublish
SO  - Vopr Pitan. 2015;84(6):76-82.